We are delighted to welcome you to our Internet site and we would like to thank all of our new and traditional shareholders for their confidence and support.
Preventing or reducing bleeding on the operating table represents a crucial challenge in surgery that enables operating times to be reduced, performances to be improved – during both complex operations and minimally invasive surgery – and patients’ health to be protected.
Our flagship product, HEMOBLAST™ Bellows, is a best-in-class hemostatic product that aims to control bleeding during surgical operations (spine surgery, heart surgery, general surgery, orthopedic surgery, etc.) It obtained its CE Mark in December 2016, and its PMA (Pre-Market Approval) application was granted by the FDA (Food & Drug Administration) in December 2017 with a view to commercializing in the United States over the summer in 2018.
Our goal is to become a major player on the hemostatic product market. We are thus targeting a market share of 15%1 in the United States and major European countries in 2022, on a market estimated at about 1.2 billion $.
In order to reach our objectives, we have raised almost 100 million euros since the beginning of 2017, through our initial public offering in October 2017 and a capital increase in February 2018. These funds will enable us to finance the construction of a second production unit for HEMOBLAST Bellows, to meet the expected increase in demand for hemostatic products. It will also help us support the commercial roll-out of HEMOBLAST Bellows in Europe and the United States as well as continue the preclinical studies and clinical trials with HEMOBLAST Bellows.
Rest assured that we will remain completely focused on the achievement of our projects and that we will do our best to ensure that HEMOBLAST Bellows is a global success.
The Biom’up team
1To reach this objective, the Group should initially rely on increasing production capacity at its Saint-Priest site, and secondly by commissioning a new production plant.